ライフサイエンスコーパス: PUFA

1 PUFA and oxylipin markers were tested as potential bioma

2 PUFA composition and concentrations as well as sEH activ

3 association of circulating plant-origin n-3 PUFA (ALA) but no convincing association of marine-deriv

4 Lower maternal n-3 PUFA concentrations and higher n-6 PUFA concentrations d

5 We observed that higher maternal total n-3 PUFA concentrations, and specifically those of eicosapen

6 of plasma lysophospholipids to obesity, n-3 PUFA consumption, and a high-fat meal challenge to bette

7 Here, we developed a mouse model of n-3 PUFA deficiency lasting from adolescence into adulthood.

8 ral deficits associated with nutritional n-3 PUFA deficiency.SIGNIFICANCE STATEMENT In a mouse model

9 NCE STATEMENT In a mouse model mimicking n-3 PUFA dietary deficiency during adolescence and adulthood

10 It has been hypothesized that n-3 PUFA in breast milk may assist immune and lung developme

11 ts may modify the association between LC n-3 PUFA intake and CVD risk.We determined whether a PCSK9 v

12 fatal MI risk (P-interaction = 0.003).LC n-3 PUFA intake is associated with a lower risk of nonfatal

13 e that strategies that increase maternal n-3 PUFA intake may not aid in allergic disease prevention.

14 een the PCSK9 rs11206510 genotype and LC n-3 PUFA intake on nonfatal MI risk (P-interaction = 0.012).

15 g/d) compared with low (0.28 g/d) total n-3 PUFA intake, the difference in 5-y weight change was 147

16 of a sex-dependent response of IR to an n-3 PUFA intervention.

17 (n = 26) pooled, there was no effect of n-3 PUFA on IR at the group level (SMD: 0.089; 95% CI: -0.10

18 We lowered the fetal and postnatal n-6/n-3 PUFA ratio exposure in wild-type offspring under standar

19 urated fatty acid concentrations and n-6:n-3 PUFA ratio lower for GSPC than C.

20 Recently it has been reported that n-3 PUFA status is inversely associated with type 2 diabetes

21 c complications, which was attenuated by n-3 PUFA supplementation.

22 ention, a reduction in plasma long-chain n-3 PUFA was associated with a reduction in apo CII concentr

23 ahexaenoic acid, which is one type of LC n-3 PUFA, and nonfatal MI risk (P-interaction = 0.003).LC n-

24 No associations between total n-3 PUFA, docosapentaenoic acid, and docosahexaenoic acid an

25 ized behaviors and synaptic functions in n-3 PUFA-deficient adult mice.

26 uality attributes (high sterol ester and n-3 PUFA-rich polar lipid contents).

27 nce intervals for associations of LC omega-3 PUFA (quintiled) and fish (quartiled) intake with endome

28 as mediated at least in part through omega-3 PUFA eicosanoid derivatives and by mTOR complex 1 (mTORC

29 and 6.7% (95% CI, 2.3%-10.8%) in the omega-3 PUFA group.

30 erved between total concentration of omega-3 PUFA in breastmilk and sensitization in the child up to

31 e, age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants of the FADS gene; all pheteroge

32 with a decreased ratio of omega-6-to-omega-3 PUFA through diet or fish-oil supplementation during pre

33 ed largely unchanged when breastmilk omega-3 PUFA was included in the model.

34 omega-3 polyunsaturated fatty acids (omega-3 PUFA), naturally found in echium oil (EO), can highly im

35 s of both LCPUFA and their precursor omega-3 PUFA, alpha-linolenic acid (ALA), whereas terrestrial in

36 xaenoic acid (DHA), a representative omega-3 PUFA, in wild type hairless mice induced expression of t

37 ion of a previously unknown class of omega-3 PUFA-derived lipid metabolites that originate from the c

38 iceable advantages in producing pure omega-3 PUFA.

39 es, n=468, g=-0.38, p=0.0008), and total n-3 PUFAs (six studies, n=396, g=-0.58, p=0.0001).

40 Proportions of n-3 PUFAs (very long-chain n-3 [VLC n-3; sum of eicosapentae

41 e a mutually regulating relation with LC n-3 PUFAs and also to reduce the risk of cardiovascular dise

42 AN displayed elevated n-3 PUFAs and may differ from controls in PUFA elongation an

43 and adipose tissue content of long-chain n-3 PUFAs and subsequent 5-y change in body weight and waist

44 g at proper TE e.g. 125 degrees C, where n-3 PUFAs are concentrated in the residues.

45 rther support to the rationale for using n-3 PUFAs as a treatment option for ADHD.

46 pread recognition of the essentiality of n-3 PUFAs came decades later despite compelling evidence of

47 OE3, but not APOE4, animals with dietary n-3 PUFAs decreased body-weight gain, plasma lipids, and ins

48 Starting nutritional deficits in dietary n-3 PUFAs during adolescence decreased n-3 PUFAs in both med

49 No associations between the individual n-3 PUFAs eicosapentaenoic acid, docosapentaenoic acid, and

50 t study prove a novel mechanism by which n-3 PUFAs exert protective roles in reducing Abeta accumulat

51 iet (HFD) or an HFD supplemented with 3% n-3 PUFAs from fish oil (HFD + FO) for 8 wk.

52 -control studies assessing the levels of n-3 PUFAs in blood and buccal tissues of children and adoles

53 y n-3 PUFAs during adolescence decreased n-3 PUFAs in both medial prefrontal cortex (mPFC) and nucleu

54 nstrated that SPD is able to concentrate n-3 PUFAs in MAG form by distilling at proper TE e.g. 125 de

55 A higher proportion of total VLC n-3 PUFAs in plasma at age 8 years was associated with a red

56 increase in total energy intake from LC n-3 PUFAs in protective-allele (C-allele) carriers, whereas

57 nd that these youth have a deficiency in n-3 PUFAs levels.

58 ied brain tissues clearly displayed that n-3 PUFAs markedly inhibit the activation of astrocytes and

59 d trials (RCTs) assessing the effects of n-3 PUFAs on clinical symptoms and cognition in children and

60 involved in the promoting the effects of n-3 PUFAs on the clearance of extracellular Abeta.

61 alling n=534 randomized youth with ADHD, n-3 PUFAs supplementation improves ADHD clinical symptom sco

62 alling n=214 randomized youth with ADHD, n-3 PUFAs supplementation improves cognitive measures associ

63 In summary, there is evidence that n-3 PUFAs supplementation monotherapy improves clinical symp

64 Adipose tissue content of n-3 PUFAs was not associated with 5-y change in waist circum

65 Intake of n-3 PUFAs was not associated with a 5-y change in waist circ

66 Higher levels of colostrum n-3 PUFAs were associated with increased risks of allergic r

67 Higher levels of colostrum n-3 PUFAs were associated with reduced sensitization (3.37[1

68 and adipose tissue content of long-chain n-3 PUFAs were neither consistently nor appreciably associat

69 ion (MI), modified the association of LC n-3 PUFAs with nonfatal MI risk in Costa Rican Hispanics.We

70 ral deficits associated with nutritional n-3 PUFAs' imbalance.

71 polyunsaturated fatty acids (omega-3 or n-3 PUFAs) in the pathogenesis and treatment of children and

72 in omega-3 polyunsaturated fatty acids (n-3 PUFAs) was conducted through short path distillation (SP

73 acids) with or without fish oil (rich in n-3 PUFAs).

74 kcal) diet, 2) a low fat diet containing n-3 PUFAs, 3) a high fat (41% kcal) diet rich in n-3 PUFAs,

75 s, 3) a high fat (41% kcal) diet rich in n-3 PUFAs, 4) a high fat n-6 PUFA diet, or 5) a high fat mon

76 In EPIC-InterAct, among long-chain n-3 PUFAs, alpha-linolenic acid (ALA) was inversely associat

77 anti-inflammatory effects attributed to n-3 PUFAs, in both mice and humans.

78 tivity of lysophospholipid metabolism to n-3 PUFAs.

79 nd abolishing its sensitivity to dietary n-3 PUFAs.

80 otic disorders, 153 (50.3%) received omega-3 PUFAs and 151 (49.7%) received placebo.

81 0.36)].Higher plasma percentages of omega-3 PUFAs and a lower ratio of omega-6-to-omega-3 PUFAs in t

82 mined the associations of dietary LC omega-3 PUFAs and fish with endometrial cancer risk in 47,602 Af

83 theless, the main conclusion is that omega-3 PUFAs are not effective under conditions where good qual

84 The findings suggest that omega-3 PUFAs could potentially serve as a therapeutic modality

85 omega-3 PUFAs exerted similar effects on the differentiation of

86 ates that the gatekeeper function of omega-3 PUFAs improves GI safety when administered with NSAID.

87 icate that a higher concentration of omega-3 PUFAs in breastmilk may be associated with a reduced ris

88 To determine whether treatment with omega-3 PUFAs in combination with a high-quality psychosocial in

89 UFAs and a lower ratio of omega-6-to-omega-3 PUFAs in the late-second trimester of pregnancy are asso

90 The most likely explanation is that omega-3 PUFAs lack efficacy under these conditions.

91 ventative and therapeutic effects of omega-3 PUFAs on T1D.

92 A daily dose of 1.4 g of omega-3 PUFAs or placebo (paraffin oil), plus 20 or fewer sessio

93 NOD mice, dietary intervention with omega-3 PUFAs sharply reduced the incidence of T1D, modulated th

94 a higher ratio of plasma omega-6-to-omega-3 PUFAs was associated with a higher PPWR [beta = 0.21 kg/

95 emonstrated that the serum levels of omega-3 PUFAs were negatively correlated with OA and wound size,

96 oduced a ceiling effect beyond which omega-3 PUFAs, even if effective, could not be shown to confer a

97 ene capable of converting omega-6 to omega-3 PUFAs.

98 crease (95% CI: -0.45, -0.02); total omega-3 PUFAs: beta = -0.20 kg/1% increase (95% CI: -0.36, -0.03

99 exaenoic acid (DHA), and total omega-3 (n-3) PUFA concentrations were associated with lower PPWR [EPA

100 ernal n-3 PUFA concentrations and higher n-6 PUFA concentrations during pregnancy are associated with

101 Higher maternal total n-6 PUFA concentrations, and specifically those of dihomo-ga

102 DHA vicinal diol 19,20-dihydroxy-DPA and n-6 PUFA derived 15-keto-PG E2 (15-keto-PGE2).

103 l) diet rich in n-3 PUFAs, 4) a high fat n-6 PUFA diet, or 5) a high fat monounsaturated diet.

104 s to investigate associations of n-3 and n-6 PUFA levels in colostrum and breast milk with allergic d

105 Higher serum total n-6 PUFA, LA, and AA concentrations and estimated D5D activi

106 shifts in circulating levels of n-3 and n-6 PUFA-derived bioactive lipid mediators were quantified b

107 outcome was the association between omega-6 PUFA biomarkers and incident type 2 diabetes.

108 vealed no significant differences in omega-6 PUFA serum levels between patients with AMD, DR, RVO and

109 .001) and higher concentrations of total n-6 PUFAs (HR: 0.54; 95% CI: 0.41, 0.73; P-trend < 0.001), l

110 noic acid] and alpha-linolenic acid) and n-6 PUFAs (linoleic acid and arachidonic acid [AA]) in blood

111 e investigated the associations of serum n-6 PUFAs and activities of enzymes involved in PUFA metabol

112 es observed associations between n-3 and n-6 PUFAs and allergic disease, and the magnitude of this ef

113 investigate associations between n-3 and n-6 PUFAs at age 8 years and asthma, rhinitis, and aeroaller

114 he 1950s established the essentiality of n-6 PUFAs for skin integrity; however, widespread recognitio

115 Higher levels of n-3 but not n-6 PUFAs in colostrum were associated with a trend towards

116 s of certain VLC n-3 and very long-chain n-6 PUFAs in plasma phospholipids at age 8 years were associ

117 Among n-6 PUFAs, linoleic acid (LA) (0.80; 95% CI 0.77-0.83) and e

118 rich in n-6 polyunsaturated fatty acids [n-6 PUFAs]), olive oil (rich in monounsaturated fatty acids)

119 In contrast, most omega-6 PUFAs exhibited positive correlations with OA, impaired

120 o associations were observed between omega-6 PUFAs or ruminant FAs and sensitization.

121 cids such as omega-3 (n-3) and omega-6 (n-6) PUFAs that cannot be readily synthesized by the human bo

122 ted fatty acid (PUFA)-rich diet (SFAs: 5.8%, PUFAs: 11.5%); and a low-fat, high-carbohydrate diet (fa

123 pable of reducing the neurogenic effect of a PUFA, while the inhibition of BDNF resulted in the reduc

124 lpha-linolenic acid and docosahexaenoic acid PUFAs are associated with AN diagnosis.

125 .2-5.7g/100g DM)>polyunsaturated fatty acid (PUFA) (0.8-1.5g/100g DM), whereas the Mon-thong variety

126 4) is an omega-6 polyunsaturated fatty acid (PUFA) and the main precursor to the class of lipid media

127 Maternal polyunsaturated fatty acid (PUFA) concentrations during pregnancy may have persisten

128 d the profile of polyunsaturated fatty acid (PUFA) metabolites produced by EGCs from rats and from pa

129 ing a microalgal polyunsaturated fatty acid (PUFA) synthase revealed that small RNA (sRNA)-mediated s

130 oncentration and polyunsaturated fatty acid (PUFA) to saturated fatty acid (SFA) ratio were higher an

131 tive epoxides of polyunsaturated fatty acid (PUFA) to the corresponding diols, lipidomic and metabolo

132 tty acid (MUFA), polyunsaturated fatty acid (PUFA), and saturated fatty acid (SFA) in the breast adip

133 MUFAs: 19.6%); a polyunsaturated fatty acid (PUFA)-rich diet (SFAs: 5.8%, PUFAs: 11.5%); and a low-fa

134 tty Acids (MUFA), Polyunsatured Fatty Acids (PUFA) and Palmitic Acid.

135 ing the omega-3 polyunsaturated fatty acids (PUFA) concentration at a temperature and pressure of 30

136 -tocopherol and polyunsaturated fatty acids (PUFA) decreased (p<0.05).

137 the removal of polyunsaturated fatty acids (PUFA) from the oil.

138 tion of omega-3 polyunsaturated fatty acids (PUFA) is important in the oil industries.

139 ggests that n-3 polyunsaturated fatty acids (PUFA) promote brown adipose tissue thermogenesis.

140 ghest levels of polyunsaturated fatty acids (PUFA) were achieved by the extraction with ethanol.

141 high content of polyunsaturated fatty acids (PUFA).

142 Omega-3 polyunsaturated fatty acids (PUFA, n-3 fatty acids), the key components of fish and f

143 iations between polyunsaturated fatty acids (PUFAs) and adiposity.

144 Polyunsaturated fatty acids (PUFAs) are essential to human health and can be produced

145 Polyunsaturated fatty acids (PUFAs) are hypothesized to modulate the risk of allergic

146 how n-3 and n-6 polyunsaturated fatty acids (PUFAs) are related to type 2 diabetes (T2D) is debated.

147 peroxidation of polyunsaturated fatty acids (PUFAs) at the bis-allylic position; indeed, pretreating

148 einforcement of polyunsaturated fatty acids (PUFAs) at their bis-allylic sites has been identified as

149 the long-chain polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (22:6n-3) and arachidonic ac

150 Omega-3 polyunsaturated fatty acids (PUFAs) have a highly anti-angiogenic effect in animal mo

151 acids (SFAs) or polyunsaturated fatty acids (PUFAs) have different metabolic responses.We investigate

152 UCTION: Dietary polyunsaturated fatty acids (PUFAs) have immunoregulatory properties.

153 t omega-3 (n-3) polyunsaturated fatty acids (PUFAs) improve obesity-induced insulin resistance (IR);

154 ortion of total polyunsaturated fatty acids (PUFAs) in CEs tended to increase in the intervention gro

155 of energy from polyunsaturated fatty acids (PUFAs) in the highest tertile was associated with increa

156 ility of omega3 polyunsaturated fatty acids (PUFAs) incorporated nanoliposomes in food enrichment.

157 thesis that n-3 polyunsaturated fatty acids (PUFAs) induce hypothalamic neurogenesis.

158 e conversion of polyunsaturated fatty acids (PUFAs) into their long-chain active form.

159 ficiency in n-3 polyunsaturated fatty acids (PUFAs) is a hallmark of poor nutrition and mood disorder

160 relative to n-3 polyunsaturated fatty acids (PUFAs) is believed to regulate perinatal adipogenesis, b

161 tion of omega-3 polyunsaturated fatty acids (PUFAs) is known to suppress inflammatory processes, maki

162 y n-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be able to improve these conditions.

163 ) n-3 (omega-3) polyunsaturated fatty acids (PUFAs) may vary across various ethnic populations.

164 n-3 polyunsaturated fatty acids (PUFAs) of marine origin play an important role in the re

165 t the effect of polyunsaturated fatty acids (PUFAs) on SWCNT photoluminescence.

166 and marine n-3 polyunsaturated fatty acids (PUFAs) on the development of obesity and associated card

167 roduced omega-3 polyunsaturated fatty acids (PUFAs) on ultraviolet B (UVB)-induced skin inflammation

168 er emulsions of polyunsaturated fatty acids (PUFAs) prepared from cod liver oil.

169 rich in omega-3 polyunsaturated fatty acids (PUFAs) provide beneficial anti-inflammatory effects, in

170 whereas omega-3 polyunsaturated fatty acids (PUFAs) relieve inflammation, reduce oxidative stress, an

171 ects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little evidence is availa

172 n n-3 (omega-3) polyunsaturated fatty acids (PUFAs) to a rodent diet reduces fat mass and prevents th

173 28.2-30.6%, and polyunsaturated fatty acids (PUFAs) were 26.7-29.1%.

174 d omega-6 (n-6) polyunsaturated fatty acids (PUFAs), 2) sulfated neurosteroids, which play a role in

175 e show that n-3 polyunsaturated fatty acids (PUFAs), by use of fat-1 transgenic mice and oral adminis

176 tocopherol and polyunsaturated fatty acids (PUFAs), especially eicosapentaenoic acid (EPA) and docos

177 As), especially polyunsaturated fatty acids (PUFAs), has been associated with a lower risk of ischemi

178 and trends for polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and mixture

179 in (LC) omega-3 polyunsaturated fatty acids (PUFAs), which derive primarily from intakes of fatty fis

180 g-chain omega-3 polyunsaturated fatty acids (PUFAs).

181 ion of oxidized polyunsaturated fatty acids (PUFAs).

182 activity toward polyunsaturated fatty acids (PUFAs).

183 was negatively correlated with C20:5n-3 and PUFA/SFA ratio, but differences in sensory attributes (t

184 the carbohydrate (+2.6%), MUFA (+5.3%), and PUFA (+12.3%) diets (P < 0.05 for all).

185 results indicate that total fat intake, and PUFA intake in particular, is associated with very small

186 5) compared with the carbohydrate, MUFA, and PUFA diets.

187 e to extra energy intake.SFA overfeeding and PUFA overfeeding induce distinct epigenetic changes in h

188 Furthermore, both the SFA and PUFA diets increased the mean degree of DNA methylation

189 Levels of TFA and PUFA were only stable after storage at -20 degrees C for

190 ganic acids) and lipophilic (tocopherols and PUFA) compounds.

191 ted, in which proportion of SFAs, MUFAs, and PUFAs in TAG varied by 1.3-, 3.7-, and 11.2-fold, respec

192 ith the effects of carbohydrates, MUFAs, and PUFAs, particularly in individuals with high LDL cholest

193 decrease in carotenoids, tocochromanols and PUFAs.

194 terms of presenting the association between PUFA and allergy; therefore, estimates could not be pool

195 e transposon-like silencing of canola-biased PUFA synthase transgenes.

196 oncentration and yield of the main bioactive PUFA, with the lowest formation of ethyl carbamates in t

197 Most of the neurogenic activity induced by PUFAs resulted in increased numbers of proopiomelanocort

198 (NEGR1), and proopiomelanocortin (POMC)] by PUFAs, only 125 genes [e.g., adiponectin, C1Q and collag

199 lyunsaturated fatty acids (LC-PUFA) from C18 PUFA precursors, rabbitfish Siganus canaliculatus provid

200 high elongation activity towards C18 and C20 PUFA, with only low activity towards C22 PUFA.

201 4 could effectively convert both C20 and C22 PUFA to longer polyenoic products up to C34.

202 that the ability to efficiently elongate C22 PUFA and thus to synthesize DHA through the Sprecher pat

203 C20 PUFA, with only low activity towards C22 PUFA.

204 to operate as Delta6 desaturases towards C24 PUFA enabling them to synthesise DHA through the Spreche

205 and low serum omega-3 and omega-6 long-chain PUFAs, which are essential for growth and development; l

206 published prospective studies on circulating PUFAs and T2D risk and pooled the quantitative evidence

207 ope deuterium at the site of peroxidation (D-PUFA) prevented PUFA oxidation and blocked ferroptosis.

208 graphy tandem mass spectrometry to determine PUFA signatures.

209 r preparation of site-selectively deuterated PUFAs require rather long, laborious, and expensive synt

210 ilst elevated plasma n-3 polyunsaturated FA (PUFA) was associated with a beneficially lower concentra

211 As), omega-6 or omega-3 polyunsaturated FAs (PUFAs).

212 unsaturated fat (MUFA), polyunsaturated fat (PUFA), and carbohydrate affect key metrics of glucose-in

213 In general, the 2kGy dose favoured PUFA and was the most suitable to preserve the overall p

214 The best model for PUFA was obtained for region 4000.12-650.15 using the fi

215 but higher amounts of aldehydes derived from PUFA oxidation, while in EVOO were enriched with phenoli

216 oint near the oil-water interface of a given PUFA droplet in a spatially localized two-photon photose

217 , whereas the Mon-thong variety had SFA>MUFA>PUFA (5.1, 4.0, 1.1g/100g DM, respectively).

218 gn tissue, postmenopausal women had a higher PUFA (0.35 +/- 0.06 vs 0.27 +/- 0.05; P < .01) and lower

219 However, PUFA is prone to oxidation.

220 and injected directly into the hypothalamus, PUFAs were capable of increasing hypothalamic neurogenes

221 ed n-3 PUFAs and may differ from controls in PUFA elongation and desaturation processes.

222 e partially inhibited in LI samples (high in PUFA), resulting in lower positive sensory ratings.

223 PUFAs and activities of enzymes involved in PUFA metabolism, Delta5 desaturase (D5D) and Delta6 desa

224 n lipid mediator profile, with no overlap in PUFA metabolites formed.

225 Breast milk is rich in PUFA, and it has been hypothesized that these PUFAs may

226 or the tuna by-product oil, which is rich in PUFA.

227 tions with previously less well-investigated PUFAs points to the importance of considering individual

228 scriptional regulation in response to n-3 LC-PUFA administration were investigated in vivo and in vit

229 natal intervention to modify maternal n-3 LC-PUFA intake and outcomes of allergic disease (eczema, rh

230 association between maternal fish or n-3 LC-PUFA intake during pregnancy and RCTs with a prenatal in

231 ults, the hypothesis linking maternal n-3 LC-PUFA intake to childhood allergic disease cannot unequiv

232 The omega-3 LC-PUFA metabolites from 2 groups of enzymes, cyclooxygenas

233 ssociation between increased prenatal n-3 LC-PUFA or fish intake and incidence of allergic disease sy

234 n-3 LC-PUFA suppressed transcription of the two elongase genes,

235 xygenases, inhibit [and the omega-6 (n-6) LC-PUFA metabolites promote] inflammation and angiogenesis.

236 e long-chain polyunsaturated fatty acids (LC-PUFA) from C18 PUFA precursors, rabbitfish Siganus canal

237 f long-chain polyunsaturated fatty acids (LC-PUFA) provides an intriguing example on how multi-enzyma

238 y acyl desaturases (Fad), key enzymes for LC-PUFA biosynthesis, accompanied by elevated miR-33 abunda

239 Srebp1, may be involved in regulation of LC-PUFA biosynthesis by facilitating fad expression, probab

240 for studying the regulatory mechanisms of LC-PUFA biosynthesis in teleosts.

241 nding protein 1 (Srebp1), an activator of LC-PUFA biosynthesis.

242 nderstanding of the mechanisms regulating LC-PUFA biosynthesis in marine fish species.

243 Here we examine key components of the LC-PUFA cascade, the Elovl2/Elovl5 elongases, from amphioxu

244 nding of the roles of omega-3 and omega-6 LC-PUFAs and their enzymatic metabolites in neovascular eye

245 ) long-chain polyunsaturated fatty acids (LC-PUFAs) reduce retinal and choroidal angiogenesis.

246 3 long-chain polyunsaturated fatty acids (LC-PUFAs), docosahexaenoic acid (DHA, C22:6) and eicosapent

247 esaturase activities and plasma and membrane PUFAs towards greater anti-inflammatory profiles.

248 idence, the associations between breast milk PUFA and allergic disease have not previously been syste

249 f isocaloric replacements between SFA, MUFA, PUFA, and carbohydrate, adjusted for protein, trans fat,

250 undance ratio that underlie a rigid SFA:MUFA:PUFA hierarchy in triacylglycerol (TAG).

251 convincing association of marine-derived n3 PUFAs (EPA and DHA) with T2D.

252 ass finished beef, while higher levels of n6 PUFAs in grain finished animals may promote inflammation

253 er, they highlight that the most abundant n6-PUFA (LA) is inversely associated with T2D.

254 e selenocysteine, leading to accumulation of PUFA hydroperoxides.

255 l data exist using circulating biomarkers of PUFA intake and metabolism.

256 lenocysteine in Gpx4 prevents elimination of PUFA hydroperoxides; these findings suggest new strategi

257 All prior studies investigating the KIE of PUFA oxygenation have relied on in vitro systems using p

258 newly developed method, had higher levels of PUFA, total vitamin E, gamma-oryzanol, hydrobenzoic acid

259 londialdehyde (MDA), an archetypal marker of PUFA oxidation.

260 The reduction of PUFA is the consequence of the increase of peroxides and

261 e oxidative changes of fatty acid signals of PUFA concentrate during accelerated storage.

262 t of storage temperature on the stability of PUFA in ground and freeze-dried seaweed biomass was inve

263 s (FFAs) from flaxseed oil, concentration of PUFAs, and enzymatic esterification by the Celite-immobi

264 ic protocol for site-specific deuteration of PUFAs and analogous poly-alkenes under exceptional kinet

265 on (E11(-)) were observed in the presence of PUFAs.

266 reover, significantly (p<0.01) higher omega3 PUFAs % recovery and lower peroxide and anisidine values

267 h unencapsulated or microencapsulated omega3 PUFAs showed significant (p=0.02) fishy flavor.

268 ated (fish oil) and microencapsulated omega3 PUFAs.

269 microencapsulated, and nanoliposomal omega3 PUFAs enriched foods.

270 values were observed in nanoliposomal omega3 PUFAs enriched samples in comparison with other samples.

271 nce between control and nanoliposomal omega3 PUFAs enriched samples while, samples enriched with unen

272 Nanoliposomal omega3 PUFAs was prepared by Mozafari method, and their applica

273 eproducible method for application of omega3 PUFAs in the food system was developed.

274 effects of 7 wk of excessive SFA (n = 17) or PUFA (n = 14) intake (+750 kcal/d) on the DNA methylatio

275 th quintile 1: 0.45 (95% CI: 0.28, 0.72)] or PUFAs [HR: 0.66 (95% CI: 0.44, 0.98)], whereas HRs in ci

276 itized to Ca(2+) by the presence of oxidized PUFAs.

277 wk of gestation, plasma phosphatidylcholine PUFA concentrations were measured and determined as perc

278 Plasma phospholipid PUFAs were measured by gas chromatography among 12,132 i

279 examined the association of maternal plasma PUFAs in pregnancy with 18-mo postpartum weight retentio

280 the site of peroxidation (D-PUFA) prevented PUFA oxidation and blocked ferroptosis.

281 caprilic, undecanoic, 9c, 11tCLA, SigmaCLA, PUFA, omega3, omega6, retinol and alpha-tocopherol.

282 alence of SNPs that are associated with slow PUFA conversion has been described in Hispanic populatio

283 In summary, we found that PUFA oxidation by lipoxygenases via a PHKG2-dependent ir

284 ence of a novel antitumoral mechanism of the PUFA arachidonic acid (AA).

285 Besides, subsequent washing steps of the PUFA fraction with water were efficient to remove the ur

286 FAT atypical cadherin 1 (FAT1)], whereas the PUFA diet did not significantly affect gene expression.

287 In lentils, the PUFAs% ranged from 42.0% to 57.4%, while in Azuki beans

288 UFA, and it has been hypothesized that these PUFAs may be important in the aetiology of allergic dise

289 Thus, PUFAs emerge as a potential dietary approach to correct

290 ting the decrease in the proportion of total PUFAs and linoleic acid and by increasing the proportion

291 The proportion of total PUFAs in phospholipids (P = 0.019 for group x time inter

292 s) was theoretically replaced by total UFAs, PUFAs, or cis monounsaturated fatty acids (MUFAs).

293 placement of SFAs plus TFAs with total UFAs, PUFAs, or cis MUFAs (per 5% of energy) was associated wi

294 ghly affected by the degree of unsaturation, PUFA being the fatty acids that showed the highest resis

295 lyunsaturated fatty acids including n-3 (VLC-PUFAs,n-3).

296 and neuronal dysfunctions, the roles of VLC-PUFAs remain unknown.

297 cells that are oxygenated derivatives of VLC-PUFAs,n-3; we termed these mediators elovanoids (ELV).

298 The resulting product contained 50% (w/w) PUFAs, including 42% (w/w) alpha-linolenic and 9.7% (w/w

299 It is unclear whether PUFAs in pregnancy have an effect on maternal weight ret

300 consistent favourable effects were seen with PUFA, which was linked to improved glycaemia, insulin re

301 lic position; indeed, pretreating cells with PUFAs containing the heavy hydrogen isotope deuterium at